IN8bio closed at $0.83 on Nov 5, down 10.82%, within 0.0% of its 52-week closing low. Volume of 43.6K shares was 1.15× its 20-day average (close to normal).
Split-adjusted performance: -40.7% over one month, -48.1% over six months, -49.7% over one year.
Short interest was 32.8K shares at the Oct 15 settlement, down 29.4% from the prior report (0.5% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INABIN8bio | $0.8300 | −10.82% | −48.1% | — | — | — | $8.2M | |
| INTSIntensity Therapeutics | $3.10 | −11.43% | −39.3% | — | — | — | $10.1M | Compare |
| SNTISenti Biosciences Holdings | $0.1645 | −6.85% | −83.3% | — | −75000.0% | — | $6.3M | Compare |
| AIMAIM ImmunoTech | $0.1521 | −5.53% | −72.8% | +4.0% | −26876.9% | — | $6.1M | Compare |
| PASGPassage Bio | $3.46 | −1.42% | −15.2% | — | — | — | $11.1M | Compare |
| SCLXScilex Holding | $1.70 | −7.10% | −78.9% | −22.8% | −1501.3% | — | $12.0M | Compare |
| TCRXTScan Therapeutics | $0.1818 | −13.43% | −85.0% | −65.8% | −2888.6% | — | $12.3M | Compare |
| BCDABioCardia | $0.8900 | −2.53% | −18.3% | — | — | — | $13.5M | Compare |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
